Lung metastases from melanoma: when is surgical treatment warranted?

Abstract

Surgical treatment of lung metastases from melanoma is highly controversial as the expected outcome is much poorer than for other primary tumours and a reliable system for selecting patients is lacking. This study evaluated the long-term results of lung metastasectomy for melanoma, with the aim of defining a subset of patients with better prognosis. By reviewing the data of the International Registry of Lung Metastases (IRLM), we identified 328 patients who underwent lung metastasectomy for melanoma in the period 1945-1995. Survival was calculated by Kaplan-Meier estimate, using log-rank test and Cox regression model for statistical analysis. After complete pulmonary metastasectomy (282 patients) the 5- and 10-year survival was 22% and 16%, respectively. In this group of patients, a time to pulmonary metastases (TPM) shorter than 36 months or the presence of multiple metastases were independent unfavourable prognostic factors. There were no long-term survivors after incomplete resection (46 patients, P 36 months and single lesion) experienced the best survival (29% at 5 years), followed by those with one risk factor only (20% at 5 years). On the other hand, those with two risk factors or incomplete resection showed a significantly poorer survival (7% and 0% at 5 years). Surgery plays an important role in carefully selected cases of pulmonary metastatic melanoma. The prognostic grouping system proposed by the International Registry of Lung Metastases provides a simple and effective method for improving the selection of surgical candidates.

References 15

1. 1.

   Cahan W. G. Excision of melanoma metastases to lung: problems in diagnosis and management. Ann Surg. 1973;178(6):703-709.

   Not in our library10.1097/00000658-197312000-00005

2. 2.

   Falkson C. I., Ibrahim J., Kirkwood J. M., Coates A. S., Atkins M. B., Blum R. H. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1998;16(5):1743-1751.

   Not in our library10.1200/jco.1998.16.5.1743

3. 3.

   Fletcher W. S., Pommier R. F., Lum S., Wilmarth T. J. Surgical treatment of metastatic melanoma. Am J Surg. 1998;175(5):413-417.

   Not in our library10.1016/s0002-9610(98)00041-5

4. 4.

   Gorenstein L. A., Putnam J. B., Natarajan G., Balch C. A., Roth J. A. Improved survival after resection of pulmonary metastases from malignant melanoma. Ann Thorac Surg. 1991;52(2):204-210.

   Not in our library10.1016/0003-4975(91)91337-u

5. 5.

   Harpole D. H., Johnson C. M., Wolfe W. G., George S. L., Seigler H. F. Analysis of 945 cases of pulmonary metastatic melanoma. J Thorac Cardiovasc Surg. 1992;103(4):743-750.

   Not in our library

6. 6.

   Holder W. D., White R. L., Zuger J. H., Easton E. J., Greene F. L. Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann Surg. 1998;227(5):764-771.

   Not in our library10.1097/00000658-199805000-00017

7. 7.

   Karakousis C. P., Velez A., Driscoll D. L., Takita H. Metastasectomy in malignant melanoma. Surgery. 1994;115(3):295-302.

   Not in our library

8. 8.

   Mathisen D. J., Flye M. W., Peabody J. The role of thoracotomy in the management of pulmonary metastases from malignant melanoma. Ann Thorac Surg. 1979;27(4):295-299.

   Not in our library10.1016/s0003-4975(10)63302-4

9. 9.

   Mountain C. F., McMurtrey M. J., Hermes K. E. Surgery for pulmonary metastasis: a 20-year experience. Ann Thorac Surg. 1984;38(4):323-330.

   Not in our library10.1016/s0003-4975(10)62280-1

10. 10.

    Ollila D. W., Stern S. L., Morton D. L. Tumor doubling time: a selection factor for pulmonary resection of metastatic melanoma. J Surg Oncol. 1998;69(4):206-211.

    Not in our library10.1002/(sici)1096-9098(199812)69:4<206::aid-jso3>3.0.co;2-n

11. 11.

    Pogrebniak H. W., Stovroff M., Roth J. A., Pass H. I. Resection of pulmonary metastases from malignant melanoma: results of a 16-year experience. Ann Thorac Surg. 1988;46(1):20-23.

    Not in our library10.1016/s0003-4975(10)65845-6

12. 12.

    Slingluff C. L., Dodge R. K., Stanley W. E., Seigler H. F. The annual risk of melanoma progression. Implications for the concept of cure. Cancer. 1992;70(7):1917-1927.

    Not in our library10.1002/1097-0142(19921001)70:7<1917::aid-cncr2820700719>3.0.co;2-5

13. 13.

    Tafra L., Dale P. S., Wanek L. A., Ramming K. P., Morton D. L. Resection and adjuvant immunotherapy for melanoma metastatic to the lung and thorax. J Thorac Cardiovasc Surg. 1995;110(1):119-129.

    Not in our library10.1016/s0022-5223(05)80017-0

14. 14.

    Thayer J. O., Overholt R. H. Metastatic melanoma to the lung: long-term results of surgical excision. Am J Surg. 1985;149(4):558-562.

    Not in our library10.1016/s0002-9610(85)80056-8

15. 15.

    Wong J. H., Skinner K. A., Kim K. A., Foshag L. J., Morton D. L. The role of surgery in the treatment of nonregionally recurrent melanoma. Surgery. 1993;113(4):389-394.

    Not in our library

Cited by papers we hold 1

• Therapy for metastatic melanoma: the past, present, and future · 2012
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.